Efficient production of recombinant IL-21 proteins for pre-clinical studies by a two-step dilution refolding method

Zhian Chen Chen; Yanfang Cui; Yew Ann Leong; Di Yu

doi:10.1016/j.intimp.2013.02.017

Efficient production of recombinant IL-21 proteins for pre-clinical studies by a two-step dilution refolding method

Zhian Chen Chen, Yanfang Cui, Yew Ann Leong, Di Yu

Research output: Contribution to journal › Article › Research › peer-review

6 Citations (Scopus)

Abstract

Produced by CD4+ helper T cells and natural killer T (NKT) cells, interleukin-21 (IL-21) performs broad regulatory functions on B cells, CD4+ T cells, CD8+ T cells, NK cells and NKT cells. Targeting IL-21 to enhance the immune system has attracted great interests in the development of vaccination, anti-infection and anti-tumor therapies. Administration of IL-21 in pre-clinical models is however limited by relatively high expense of the recombinant IL-21 protein. Here, we report a rapid and cost-effective method to produce IL-21 using Escherichia coli (E. coli) by introducing a novel two-step dilution strategy for refolding. The method has been validated to produce milligrams of human IL-21, human IL-21/IL-4 chimera and mouse IL-21 with high bioactivities and low endotoxin, mostly suitable for in vitro and in vivo pre-clinical studies.

Original language	English
Pages (from-to)	376 - 381
Number of pages	6
Journal	International Immunopharmacology
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/j.intimp.2013.02.017
Publication status	Published - 2013

Access to Document

10.1016/j.intimp.2013.02.017

RM sElocation

Cite this

@article{e3ef185a22864152974156b42c6f95d1,

title = "Efficient production of recombinant IL-21 proteins for pre-clinical studies by a two-step dilution refolding method",

abstract = "Produced by CD4+ helper T cells and natural killer T (NKT) cells, interleukin-21 (IL-21) performs broad regulatory functions on B cells, CD4+ T cells, CD8+ T cells, NK cells and NKT cells. Targeting IL-21 to enhance the immune system has attracted great interests in the development of vaccination, anti-infection and anti-tumor therapies. Administration of IL-21 in pre-clinical models is however limited by relatively high expense of the recombinant IL-21 protein. Here, we report a rapid and cost-effective method to produce IL-21 using Escherichia coli (E. coli) by introducing a novel two-step dilution strategy for refolding. The method has been validated to produce milligrams of human IL-21, human IL-21/IL-4 chimera and mouse IL-21 with high bioactivities and low endotoxin, mostly suitable for in vitro and in vivo pre-clinical studies.",

author = "Chen, {Zhian Chen} and Yanfang Cui and Leong, {Yew Ann} and Di Yu",

year = "2013",

doi = "10.1016/j.intimp.2013.02.017",

language = "English",

volume = "16",

pages = "376 -- 381",

journal = "International Immunopharmacology",

issn = "1567-5769",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Efficient production of recombinant IL-21 proteins for pre-clinical studies by a two-step dilution refolding method

AU - Chen, Zhian Chen

AU - Cui, Yanfang

AU - Leong, Yew Ann

AU - Yu, Di

PY - 2013

Y1 - 2013

N2 - Produced by CD4+ helper T cells and natural killer T (NKT) cells, interleukin-21 (IL-21) performs broad regulatory functions on B cells, CD4+ T cells, CD8+ T cells, NK cells and NKT cells. Targeting IL-21 to enhance the immune system has attracted great interests in the development of vaccination, anti-infection and anti-tumor therapies. Administration of IL-21 in pre-clinical models is however limited by relatively high expense of the recombinant IL-21 protein. Here, we report a rapid and cost-effective method to produce IL-21 using Escherichia coli (E. coli) by introducing a novel two-step dilution strategy for refolding. The method has been validated to produce milligrams of human IL-21, human IL-21/IL-4 chimera and mouse IL-21 with high bioactivities and low endotoxin, mostly suitable for in vitro and in vivo pre-clinical studies.

AB - Produced by CD4+ helper T cells and natural killer T (NKT) cells, interleukin-21 (IL-21) performs broad regulatory functions on B cells, CD4+ T cells, CD8+ T cells, NK cells and NKT cells. Targeting IL-21 to enhance the immune system has attracted great interests in the development of vaccination, anti-infection and anti-tumor therapies. Administration of IL-21 in pre-clinical models is however limited by relatively high expense of the recombinant IL-21 protein. Here, we report a rapid and cost-effective method to produce IL-21 using Escherichia coli (E. coli) by introducing a novel two-step dilution strategy for refolding. The method has been validated to produce milligrams of human IL-21, human IL-21/IL-4 chimera and mouse IL-21 with high bioactivities and low endotoxin, mostly suitable for in vitro and in vivo pre-clinical studies.

UR - http://goo.gl/hpktG8

U2 - 10.1016/j.intimp.2013.02.017

DO - 10.1016/j.intimp.2013.02.017

M3 - Article

VL - 16

SP - 376

EP - 381

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 3

ER -